Pfizer Inc. Release: Patients Treated with Lipitor Were Significantly Less Likely to Have a Cardiovascular Event Than Those Treated with Simvastatin, New Observational Study Shows

NEW YORK--(BUSINESS WIRE)--Results of an observational study of a large U.S. managed care claims database showed that new statin users without cardiovascular disease who took Lipitor® (atorvastatin calcium) Tablets had a significantly lower relative risk of experiencing any cardiovascular event, a heart attack, or revascularization (a type of heart surgery) compared to patients who took simvastatin.